Actelion Remains In M&A Spotlight, ASH Data In Focus

Several companies like Celgene, Alexion, Juno and Kite (KITE - Free Report) were present at the annual meeting of the American Society of Hematology (ASH) with data on approved and pipeline products.

Meanwhile, Switzerland-based Actelion (ALIOF - Free Report) continued to be a part of acquisition chatter with Sanofi now rumored to be interested in the company.

Recap of the Week’s Most Important Stories

Is Sanofi Planning to Come Up with an Offer for Actelion? Actelion, which had confirmed that it is in discussions with Johnson & Johnson, could well receive an offer from French pharma giant, Sanofi, according to a Bloombergarticle. Per sources, Sanofi is apparently considering a counterbid for Actelion and is weighing its options. The company is yet to decide whether it will approach Actelion with a formal offer.

Meanwhile, according to sources, J&J has hiked its offer though Actelion is reportedly not interested in a complete takeover. We note that Actelion has often been considered an attractive takeover target mainly due to its rare disease portfolio. In addition to holding a strong position in the pulmonary arterial hypertension (PAH) market, Actelion’s portfolio also has treatments approved in certain countries for specialist diseases like type I Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. Actelion has consistently outperformed the Zacks categorized Medical-Biomedical/Genetics industry year-to-date (YTD) with Actelion gaining 50.3% while the Zacks categorized Medical-Biomedical/Genetics industry declined 25.4%.

AbbVie at ASH, Gets Orphan Drug Status for Immunology Drug: AbbVie (ABBV - Free Report) was present at ASH with data on its cancer drug, Imbruvica. The company presented positive mid-stage data from a study in chronic graft-versus-host-disease (cGVHD) patients showing that Imbruvica has the potential to be evaluated for non-cancer ailments. Imbruvica has orphan drug status as well as breakthrough therapy designation in the U.S. for this indication.

1 2 3 4
View single page >> |

Disclosure: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Chee Hin Teh 4 years ago Member's comment

Thanks for sharing